Trial Profile
A prospective, multicenter, observational study evaluating efficacy and safety of eslicarbazepine acetate monotherapy in patients with partial-onset seizures
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Apr 2018
Price :
$35
*
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies; Seizures
- Focus Adverse reactions; Therapeutic Use
- 13 Apr 2018 New trial record